Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

1990 ◽  
Vol 32 (4) ◽  
pp. 398-398
Author(s):  
WT Creasman ◽  
S Gall ◽  
BN Bundy ◽  
J Beecham ◽  
R Mortel
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Stage Iii ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Second Look ◽  
Minimal Residual

Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group study)

1989 ◽  
Vol 35 (3) ◽  
pp. 378-382 ◽  
Author(s):  
William T. Creasman ◽  
Stanley Gall ◽  
Brian N. Bundy ◽  
Jackson Beecham ◽  
Rodrigue Mortel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Stage Iii ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Second Look ◽  
Minimal Residual

Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study.

1989 ◽  
Vol 7 (4) ◽  
pp. 466-470 ◽  
Author(s):  
L A Walton ◽  
J A Blessing ◽  
H D Homesley
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Median Number ◽  
Hematologic Toxicity ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Epithelial Cancer ◽  
Oncology Group Study ◽  
Number Of Treatment ◽  
Minimal Residual

Twenty-seven patients with ovarian cancer who had failed combination chemotherapy were offered intraperitoneal (IP) fluorouracil (5-FU) as salvage therapy in an attempt to ascertain the efficacy of such a therapeutic method. All patients had minimal residual epithelial cancer. The median number of treatment cycles was six. Major problems with dialysate inflow and egress occurred in ten patients and required discontinuation of therapy. An additional ten patients experienced hematologic toxicity with a median nadir WBC of 2,300/microL. Therapy was altered but not discontinued because of this complication. Other adverse sequelae, such as abdominal pain, were manageable with medication. IP 5-FU is technically feasible on a multiinstitutional basis in residual ovarian cancer, but its therapeutic role remains to be defined.

Sign in / Sign up

Export Citation Format

Share Document